inclusion criteria: type of participant and disease characteristics - documented or confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection by an fda-approved polymerase chain reaction test of nasopharyngeal swab or stool less than 72 hours before randomization hospitalized for covid-19 illness of any duration with at least 1 of the following: clinical assessment (evidence of rales/crackles on exam) and peripheral capillary oxygen saturation less than or equal to 94% on room air, or requiring mechanical ventilation and/or supplemental oxygen, or radiographic evidence (chest x-ray or computed tomography scan) of 1 of the following: ground-glass opacities, or local or bilateral patchy infiltrates, or interstitial pulmonary infiltrates if the participant was intubated, must have been intubated less than 24 hours prior to randomization sex and contraception guidelines - contraceptive use by men or women should have been consistent with local regulations regarding the methods of contraception for those participating in clinical studies. informed consent - capable of giving signed informed consent or by a designated representative, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol

inclusion criteria: type of participant and disease characteristics - documented or confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection by an fda-approved polymerase chain reaction test of nasopharyngeal swab or stool less than 72 hours before randomization hospitalized for covid-19 illness of any duration with at least 1 of the following: clinical assessment (evidence of rales/crackles on exam) and peripheral capillary oxygen saturation less than or equal to 94% on room air, or requiring mechanical ventilation and/or supplemental oxygen, or radiographic evidence (chest x-ray or computed tomography scan) of 1 of the following: ground-glass opacities, or local or bilateral patchy infiltrates, or interstitial pulmonary infiltrates if the participant was intubated, must have been intubated less than 24 hours prior to randomization sex and contraception guidelines - contraceptive use by men or women should have been consistent with local regulations regarding the methods of contraception for those participating in clinical studies. informed consent - capable of giving signed informed consent or by a designated representative, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol

inclusion criteria: type of subject and disease characteristics documented or confirmed sars-cov-2 infection by an fda-approved pcr test of nasopharyngeal swab or stool less than 72 hours before randomization. hospitalized for covid-19. illness of any duration with at least one of the following clinical assessment (evidence of rales/crackles on exam) and spo2 less than or equal to 94% on room air, or requiring mechanical ventilation and/or supplemental oxygen, or radiographic evidence (chest x-ray or ct scan) of one of the following: ground-glass opacities, or local or bilateral patchy infiltrates, or interstitial pulmonary infiltrates if the subject is intubated, must have been intubated less than 24 hours prior to randomization. sex and contraception guidelines contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. informed consent capable of giving signed informed consent or by a designated representative which includes compliance with the requirements and restrictions listed in the icf and in this protocol.

inclusion criteria: type of subject and disease characteristics documented or confirmed sars-cov-2 infection by an fda-approved pcr test of nasopharyngeal swab or stool less than 72 hours before randomization. hospitalized for covid-19. illness of any duration with at least one of the following clinical assessment (evidence of rales/crackles on exam) and spo2 less than or equal to 94% on room air, or requiring mechanical ventilation and/or supplemental oxygen, or radiographic evidence (chest x-ray or ct scan) of one of the following: ground-glass opacities, or local or bilateral patchy infiltrates, or interstitial pulmonary infiltrates if the subject is intubated, must have been intubated less than 24 hours prior to randomization. sex and contraception guidelines contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. informed consent capable of giving signed informed consent or by a designated representative which includes compliance with the requirements and restrictions listed in the icf and in this protocol.

inclusion criteria: type of subject and disease characteristics 1. documented or confirmed sars-cov-2 infection by an fda-approved pcr test of nasopharyngeal swab or stool less than 72 hours before randomization. 2. hospitalized for covid-19. 3. illness of any duration with at least one of the following 1. clinical assessment (evidence of rales/crackles on exam) and spo2 less than or equal to 94% on room air, or 2. requiring mechanical ventilation and/or supplemental oxygen, or 3. radiographic evidence (chest x-ray or ct scan) of one of the following: - ground-glass opacities, or - local or bilateral patchy infiltrates, or - interstitial pulmonary infiltrates 4. if the subject is intubated, must have been intubated less than 24 hours prior to randomization. sex and contraception guidelines 5. contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. informed consent 6. capable of giving signed informed consent or by a designated representative which includes compliance with the requirements and restrictions listed in the icf and in this protocol.

inclusion criteria: type of subject and disease characteristics 1. documented or confirmed sars-cov-2 infection by an fda-approved pcr test of nasopharyngeal swab or stool less than 72 hours before randomization. 2. hospitalized for covid-19. 3. illness of any duration with at least one of the following 1. clinical assessment (evidence of rales/crackles on exam) and spo2 less than or equal to 94% on room air, or 2. requiring mechanical ventilation and/or supplemental oxygen, or 3. radiographic evidence (chest x-ray or ct scan) of one of the following: - ground-glass opacities, or - local or bilateral patchy infiltrates, or - interstitial pulmonary infiltrates 4. if the subject is intubated, must have been intubated less than 24 hours prior to randomization. sex and contraception guidelines 5. contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. informed consent 6. capable of giving signed informed consent or by a designated representative which includes compliance with the requirements and restrictions listed in the icf and in this protocol.